Skip to main content
. Author manuscript; available in PMC: 2016 Feb 15.
Published in final edited form as: Clin Cancer Res. 2014 Dec 18;21(4):712–720. doi: 10.1158/1078-0432.CCR-14-2468

Figure 3.

Figure 3

Baseline biomarker assays (pretreatment). A, lower baseline CD25+Treg/CD4+ populations were observed in patients who remained disease free (nonrelapsed) with therapy (P = 0.0583). B, a trend for lower MDSC levels (CD11b+/DRlow/ CD14+) was observed in patients who remained disease free with therapy (P = 0.1718). C and D, no statistical association was observed between PD-L1 tumor status (at either a 1% or 5% cutoff) and RFS by log-rank test.